Jonathan Strosberg, MD
Lutathera (lutetium Lu 177 dotatate) continued to demonstrate a statistically meaningful progression-free survival (PFS) and quality-of-life (QoL) benefit in patients with midgut neuroendocrine tumors (NETs), according to updated data of the NETTER-1 trial presented at the 2018 ASCO Annual Meeting.
At the time the data were presented, the median overall survival (OS) for patients treated with Lutathera was not reached. Those treated with high-dose octreotide demonstrated a median OS of 27.4 months.
... to read the full story